Evaluating CVD Medication Adherence Program in Low SES (CVDMAT)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The investigators propose to evaluate the implementation of a medication adherence program among patients who attend Duke Outpatient Clinic (DOC). It is anticipated that, among the providers' patient panels, at least 100 and up to 300 with CVD risk and poor CVD medication adherence (<0.08 medication possession ratio) will consent to the program.
Using procedures from the investigators previous studies, the investigators will identify potential patients from the EHR, and will identify a pool of potential patients using electronic health records, with the goal of administering the program to at least 100 patients. Patients will be mailed letters, signed by their own provider or medical director of DOC, requesting their participation in the programs. The RA will contact patients via telephone to explain the study, screen for eligibility, and determine what mode of administration individuals prefer to receive the program (SMS, IVR, or email).
The primary outcome will be that the effectiveness/impact of the proposed adherence program will be a 10% improvement in MPR and CVD outcomes (anticipate reducing SBP by 5 mmHg, Hgb a1c by 0.5%, LDL-C by 20 mg/dl).
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University Health System Clinic
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Medicaid recipient (preferred); however the investigators will include those patients with other types of insurance or those who are uninsured
- Enrolled in Duke Outpatient Clinic for at least one year
- Outpatient diagnostic code for hypertension and/or hypercholesterolemia and/or diabetes
- Poorly controlled BP levels (>140/90) and/or LDL-C (>130mg/dl) and/or HbA1c of >8 within last 6 months
Exclusion Criteria:
- No access to cell phone
- Not proficient in English
- Nursing home/long-term care facility resident or receiving home health care
- Impaired hearing/ speech/ vision
- Participating in another trial (pharmaceutical or behavioral)
- Planning to leave the area in the next 12 months
- Pregnancy (or planning)
- Diagnosis of life-threatening disease with death probable within 1 year
- Active Diagnosis of psychosis or dementia (has been hospitalized in the last 30 days)
- Diagnosis of ESRD
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: m-health
Patients will receive text message, emails, and monthly phone calls
|
Patients will receive e-reminders via text message and email.
A message library that allows us to disseminate constant and reliable information has been created.
Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence.
In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to the program's intervention
Prazo: 6 months
|
It is measured as the proportion of technology or interventionist contacts responded to by a patient out of those received over the course of the intervention period.
This will be summarized descriptively by type of contact (technology vs. interventionist call) and subdivided by technology (SMS, email).
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical effectiveness/impact of the program to pill refill adherence
Prazo: 6 months
|
This will be measured by pulling pill refill records of those patients who are enrolled.
The investigators anticipate an improvement of 10% on pill refill adherence.
|
6 months
|
|
Clinical effectiveness/impact on BP
Prazo: 6 months
|
This will be measured by assessing systolic BP values.
The investigators anticipate reducing SBP by 5 mmHg.
|
6 months
|
|
Clinical effectiveness/impact on A1C
Prazo: 6 months
|
This will be measured by assessing A1C values.
The investigators anticipate reducing Hgb A1c by 0.5%.
|
6 months
|
|
Clinical effectiveness/impact on cholesterol
Prazo: 6 months
|
This will be measured by assessing LDL-C levels in patients.
The goal is to reduce LDL-C levels by 20 mg/dl.
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Hayden Bosworth, PhD, Duke University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Pro00054572
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .